HC Wainwright & Co. Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Positive 78.7%

Neg 0% Neu 0% Pos 78.7%

HC Wainwright & Co. analyst Joseph Pantginis maintains Rigel Pharmaceuticals (NASDAQ:RIGL) with a Buy and raises the price target from $57 to $85.